More recently, Gangemi et al. showed that silencing of the SOX2 in freshly derived glioblastoma tumor-initiating cells (TICs) stopped proliferation and the resulting cells lost tumorigenicity in immunodeficient mice [19]. This evidence concerns the gene SOX2 and neoplasm.